- Global Pharma News & Resources

VenatoRx Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference

VenatoRx Pharmaceuticals, a world leader in antibacterial and antiviral drug research and development, announced that its Chief Business Officer, Tony Meehan, MBA, PhD, will present at the 2019 BIO CEO & Investor Conference.

Presentation Details:
Date: Monday, February 11, 2019
Time: 3:30pm ET
Location: New York Marriott Marquis (Gramercy room)

About VenatoRx Pharmaceuticals, Inc.

VenatoRx is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. VenatoRx’s lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents. For more information, please visit

View source version on

Editor Details

Last Updated: 06-Feb-2019